A new day in preventing meningococcal disease: Sizing up the available vaccines

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

Six medical societies, including the American Academy of Pediatrics, are suing the HHS and its Secretary to "defend vaccine policy."

Though the original target action date was not met by the FDA, KalVista's sebetralstat is now approved to treat HAE in patients 12 years and older.